摘要
Acute kidney injury (AKI) is increasingly identified as a crucial risk factor for progression to CKD. However, the factors gov-erning AKI to CKD progression remain largely unknown. By high-throughput RNA sequencing, we found that Neat1_2, a transcript variant of Neat1, was upregulated in 40-min ischemia/reperfusion injury (IRI), which resulted in the devel-opment of renal fibrotic lesions. The upregulation of Neat1_2 in hypoxia-treated TECs was attributed to p53 transcriptional regulation. Gain-and loss-of-function studies, both in vitro and in vivo, demonstrated that Neat1_2 promoted apoptosis of injured TECs induced by IRI and caused tubulointerstitial inflammation and fibrosis. Mechanistically, Neat1_2 shares miRNA response elements with FADD, CASP-8, and CASP-3. Neat1_2 competitively binds to miR-129-5p and prevents miR-129-5p from decreasing the levels of FADD, CASP-8, and CASP-3, and ultimately facilitates TEC apoptosis. Increased expression of Neat1_2 associated with kidney injury and TEC apoptosis was recapitulated in human AKI, highlighting its clinical relevance. These findings suggest that preventing TEC apoptosis by hindering Neat1_2 expression may be a po-tential therapeutic strategy for AKI to CKD progression.
学科与关键词
- NFAT inhibitor 11R-VIVIT ameliorates mouse renal fibrosis after ischemia-reperfusion-induced acute kidney injuryXie, Zhi-yong; Dong, Wei; Zhang, Li; Wang, Meng-jie; Xiao, Zhen-meng; Zhang, Yu-hua; Shi, Wan-xin; Huang, Ying; Yang, Yan; Li, Cui-li; Fu, Lei; Zhao, Xing-chen; Li, Rui-zhao; Li, Zhi-lian; Chen, Yuan-han; Ye, Zhi-ming; Liu, Shuang-xin; Dong, Zheng; Liang, Xin-ling*Acta Pharmacologica Sinica, 2022, 43(8): 2081-2093.被引 7
- Antagonist targeting miR-106b-5p attenuates acute renal injury by regulating renal function, apoptosis and autophagy via the upregulation of TCF4Hu, Jing-Meng; He, Li-Jie; Wang, Peng-Bo; Yu, Yan; Ye, Ya-Ping; Liang, Li*International Journal of Molecular Medicine, 2021, 48(3): 169.被引 6
- MicroRNA-483-5p accentuates cisplatin-induced acute kidney injury by targeting GPX3Xia, Ying; Pan, Wenbin; Xiao, Xiao; Zhou, Xuejuan; Gu, Wenqing; Liu, Yaqin; Zhao, Yanyan; Li, Lixia; Zheng, Chenghao; Liu, Jun*; Li, Ming*Laboratory Investigation, 2022, 102(6): 589-601.被引 8
